Gp100:209-217(210M)
Gp100:209-217(210M)
Gp100:209-217(210M) (pronounced as G-P-one-hundred-two-hundred-and-nine-to-two-hundred-and-seventeen-two-hundred-and-ten-M) is a modified peptide derived from the melanoma antigen gp100.
Etymology
The term "Gp100:209-217(210M)" refers to the specific sequence of the peptide, with the numbers indicating the position of the amino acids in the sequence. The "(210M)" denotes a modification at the 210th position.
Usage
Gp100:209-217(210M) is used in cancer immunotherapy to stimulate the immune system to attack melanoma cells. It is often used in conjunction with other treatments such as interleukin-2 (IL-2).
Related Terms
- Melanoma: A type of skin cancer that originates from melanocytes.
- Gp100: A protein that is overexpressed in melanoma cells and is the source of the Gp100:209-217(210M) peptide.
- Cancer Immunotherapy: A type of treatment that uses the body's immune system to fight cancer.
- Interleukin-2 (IL-2): A type of cytokine signaling molecule in the immune system that is often used in cancer immunotherapy.
External links
- Medical encyclopedia article on Gp100:209-217(210M)
- Wikipedia's article - Gp100:209-217(210M)
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski